EP1888618A4 - Analogues de glycyl-prolyl-glutamate - Google Patents

Analogues de glycyl-prolyl-glutamate

Info

Publication number
EP1888618A4
EP1888618A4 EP06770950A EP06770950A EP1888618A4 EP 1888618 A4 EP1888618 A4 EP 1888618A4 EP 06770950 A EP06770950 A EP 06770950A EP 06770950 A EP06770950 A EP 06770950A EP 1888618 A4 EP1888618 A4 EP 1888618A4
Authority
EP
European Patent Office
Prior art keywords
glycyl
prolyl
glutamate
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06770950A
Other languages
German (de)
English (en)
Other versions
EP1888618A2 (fr
Inventor
Margaret Anne Brimble
Paul William Richard Harris
Frank Sieg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of EP1888618A2 publication Critical patent/EP1888618A2/fr
Publication of EP1888618A4 publication Critical patent/EP1888618A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP06770950A 2005-05-23 2006-05-23 Analogues de glycyl-prolyl-glutamate Withdrawn EP1888618A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68381305P 2005-05-23 2005-05-23
PCT/US2006/019909 WO2006127702A2 (fr) 2005-05-23 2006-05-23 Analogues de glycyl-prolyl-glutamate

Publications (2)

Publication Number Publication Date
EP1888618A2 EP1888618A2 (fr) 2008-02-20
EP1888618A4 true EP1888618A4 (fr) 2009-07-15

Family

ID=37452742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06770950A Withdrawn EP1888618A4 (fr) 2005-05-23 2006-05-23 Analogues de glycyl-prolyl-glutamate

Country Status (3)

Country Link
EP (1) EP1888618A4 (fr)
JP (1) JP2008545697A (fr)
WO (1) WO2006127702A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5220724B2 (ja) * 2006-03-14 2013-06-26 ニューレン ファーマシューティカルズ リミテッド グリシル−２−メチルプロリルグルタミン酸塩の経口製剤
EP2170312A1 (fr) * 2007-07-06 2010-04-07 University Of Zurich Procédé de prévention et de traitement de pathologies cérébrales aiguës
JP2010539067A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのＧｌｙ−Ｐｒｏ−Ｇｌｕ−ＯＨ（ＧＰＥ）の使用
WO2009039981A2 (fr) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
GB2489382A (en) * 2011-01-19 2012-09-26 Galapagos Nv Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
RS56461B1 (sr) * 2011-01-27 2018-01-31 Neuren Pharmaceuticals Ltd Tretman bolesti iz spektra autizma upotrebom glicil-l-2-metilprolil-l-glutaminske kiseline
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
WO2014085480A1 (fr) * 2012-11-28 2014-06-05 Neuren Pharmaceuticals Limited Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique
CN103275106B (zh) * 2013-04-19 2015-09-30 暨南大学 一种吲哚生物碱加合物及其制备方法和在制备抗肿瘤药物中的应用
CN114667136A (zh) * 2019-08-05 2022-06-24 诺仁制药有限公司 Trofinetide的组合物
GB202102709D0 (en) * 2021-02-25 2021-04-14 Univ Southampton Compounds
CN113135983B (zh) * 2021-04-12 2022-06-24 四川大学华西医院 一种抗肿瘤化合物及其制剂和制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094856A2 (fr) * 2001-05-24 2002-11-28 Neuronz Limited Peptidomimetiques et analogues de gpe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094856A2 (fr) * 2001-05-24 2002-11-28 Neuronz Limited Peptidomimetiques et analogues de gpe

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALONSO DE DIEGO S A ET AL: "Analogues of the neuroprotective tripeptide Gly-Pro-Glu (GPE): synthesis and structure-activity relationships", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 15, no. 9, 2 May 2005 (2005-05-02), pages 2279 - 2283, XP025313633, ISSN: 0960-894X, [retrieved on 20050502] *
ALONSO DE DIEGO S A ET AL: "The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 16, no. 13, 1 July 2006 (2006-07-01), pages 3396 - 3400, XP025107379, ISSN: 0960-894X, [retrieved on 20060701] *
BRIMBLE MARGARET A ET AL: "Synthesis and pharmacological evaluation of side chain modified glutamic acid analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE).", BIOORGANIC & MEDICINAL CHEMISTRY 17 JAN 2005, vol. 13, no. 2, 17 January 2005 (2005-01-17), pages 519 - 532, XP002528279, ISSN: 0968-0896 *
GILLESSEN D ET AL: "[Syntheses of thyrotropin-releasing hormones (TRH) (Schaf) and related peptides]", HELVETICA CHIMICA ACTA 1970, vol. 53, no. 1, 1970, pages 63 - 72, XP002528278, ISSN: 0018-019X *
LAI MICHELLE Y H ET AL: "Synthesis and pharmacological evaluation of glycine-modified analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE).", BIOORGANIC & MEDICINAL CHEMISTRY 17 JAN 2005, vol. 13, no. 2, 17 January 2005 (2005-01-17), pages 533 - 548, XP002528274, ISSN: 0968-0896 *
MAEHASHI K ET AL: "Isolation of peptides from an enzymatic hydrolysate of food proteins and characterization of their taste properties.", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY MAR 1999, vol. 63, no. 3, March 1999 (1999-03-01), pages 555 - 559, XP002528276, ISSN: 0916-8451 *
PARK JUNG-NIM ET AL: "Taste effects of oligopeptides in a Vietnamese fish sauce", FISHERIES SCIENCE (TOKYO), vol. 68, no. 4, August 2002 (2002-08-01), pages 921 - 928, XP002528277, ISSN: 0919-9268 *
SLOOTSTRA J W ET AL: "STRUCTURAL ASPECTS OF ANTIBODY-ANTIGEN INTERACTION REVEALED THROUGH SMALL RANDOM PEPTIDE LIBRARIES", MOLECULAR DIVERSITY, ESCOM SCIENCE PUBLISHERS, LEIDEN, NL, vol. 1, no. 2, 1 January 1995 (1995-01-01), pages 87 - 96, XP008065429, ISSN: 1381-1991 *
TROTTER NICHOLAS S ET AL: "Synthesis and neuroprotective activity of analogues of glycyl-L-prolyl-L-glutamic acid (GPE) modified at the alpha-carboxylic acid.", BIOORGANIC & MEDICINAL CHEMISTRY 17 JAN 2005, vol. 13, no. 2, 17 January 2005 (2005-01-17), pages 501 - 517, XP002528275, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
WO2006127702A2 (fr) 2006-11-30
EP1888618A2 (fr) 2008-02-20
JP2008545697A (ja) 2008-12-18
WO2006127702A3 (fr) 2007-06-14

Similar Documents

Publication Publication Date Title
ZA200700357B (en) Tetrapetide analogs
EP1928489A4 (fr) Analogues de la ghreline
EP1888618A4 (fr) Analogues de glycyl-prolyl-glutamate
MY145179A (en) Use of tetrahydrobenzoxazines as stabilizers
EP2034838A4 (fr) Nouveaux composés
PL2497780T3 (pl) Związki pokrewne TDF oraz ich analogi
EP2032142A4 (fr) Nouveaux composés
HK1161122A1 (en) Use of 24-norudca 24-norudca
EP1981596A4 (fr) Nouveaux composés
ZA200710861B (en) Uses of prostacyclin analogs
EP1981900A4 (fr) Nouveaux composés
EP1931370A4 (fr) Utilisation de des-aspartate-angiotensine i
EP2031965A4 (fr) Nouveaux composés
GB0600483D0 (en) Novel compounds
GB0609252D0 (en) Novel sytoprotective compounds
GB0607892D0 (en) Novel compounds
GB0510013D0 (en) Interaction of SNEV
TWM291236U (en) Improved structure of bookrack
TWM292330U (en) Improvement of bed-chair structure
GB0512574D0 (en) Uses of (s)-clenbuterol
IL166318A0 (en) Cortiutuo shape of sigu
PT1899354E (pt) Síntese de desoxibiotinil-hexametilenodiaminadota
TWM291301U (en) Improvement of mask structure
TWM291302U (en) Improvement of mask structure
HU0500461D0 (en) Pyperazinyl derivatives of alkyl-oxindoles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20090602BHEP

Ipc: A61P 27/00 20060101ALI20090602BHEP

Ipc: A61P 29/00 20060101ALI20090602BHEP

Ipc: C07K 5/08 20060101AFI20071220BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090615

17Q First examination report despatched

Effective date: 20091117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100528